@tompowles1 The dose intensity for cisplatin in the dd-mvac regimen is at least 25% higher than in the ddp-gem arm. No true comparison is therefore possible
The @gambitgames_arb KOL TG is now muted after concerns were raised, @50senteth has identical excuses to @0xnickfury leading me to believe they are the same team & will come out with excuses soon.
If they don't hard rug it'll prob be ded within 1 week of launch. DYOR fellas.
🎁#NFTGiveaway🎁
@BushidoRoyale was kind enough to give me 2 NFTs (free mint) to giveaway!
🏆2 NFTs🏆
To Enter✅
1⃣Join discord https://t.co/K6YbAyGEsv
2⃣Follow @BushidoRoyale
3⃣RT & Tag Frens
Founder is a fully doxxed BAYC holder, probably nothin...
#NFT#NFTGiveaway
🎁#NFTGiveaway🎁
Partnered w/ @TheDeviantsNFT to giveaway 2 Silver Mint passes!
To Enter✅
1⃣Join https://t.co/bKgulMJVYp
2⃣Follow @TheDeviantsNFT
3⃣RT & Tag Frens
Free claim Deviants by burning the mint pass TODAY March 15th 4PM UTC 🗓️👀
FORT-1 tested rogaratinib vs chemotherapy in FGFR1/3 +ve(RNA) platinum refractory UC. 600 patients screened 175 randomised (60% biomarker +ve?) Efficacy results showed regimens were very similar. Erdafitinib has a better biomarker plan. Randomised trials with erda may still be OK
Summary of 1st line advanced UC IO/chemo trials. IO can’t beat chemo and the PD-L1 biomarker doesn’t help. Chemo/IO (361,130) and Ipi/nivo in PD-L1+ve (901) were disappointing. 3 chemo/IO studies awaited for final OS, but existing data isn’t good. Still a chance for tremilimumab?